Literature DB >> 29201587

Quinolone-resistant clinical strains of Pseudomonas aeruginosa isolated from University Hospital in Tunisia.

Mouna Ben Nejma1, Olfa Sioud1, Maha Mastouri1.   

Abstract

In this study, we examined mutations in the quinolone resistance-determining regions (QRDRs) of the gyrA and parC genes of Pseudomonas aeruginosa (P. aeruginosa) clinical isolates collected from patients hospitalized in University Hospital of Monastir, Tunisia. A total of 81 P. aeruginosa strains, obtained from clinical specimens, were included in the present study. Isolates were tested against 11 different antibiotics by a disk diffusion method. Minimum inhibitory concentrations (MICs) of ciprofloxacin were evaluated by E test method. The gyrA and parC sequences genes amplified by polymerase chain reaction (PCR) were sequenced. The highest resistance rates were found for ciprofloxacin (100%), gentamicin (96%) and ticarcillin (93%). The lower resistance rates were obtained for imipenem (74%) and ceftazidime (70%). Notably, 54% of isolates resistant to ciprofloxacin were determined to be multi-drug resistant. The investigation of mutations in the nucleotide sequences of the gyrA and parC genes showed that 77% of isolates have a single mutation in both gyrA (Thr-83 → Ile) and parC (Ser-87 → Leu). The emergence of ciprofloxacin resistance in clinical P. aeruginosa requires the establishment of appropriate antibiotherapy strategies in order to prescribe the most effective antibiotic treatment for preventing the emergence of multi-drug-resistant (MDR) P. aeruginosa strains.

Entities:  

Keywords:  Ciprofloxacin; Mutations; Pseudomonas aeruginosa; Resistance; gyrA; parC

Year:  2017        PMID: 29201587      PMCID: PMC5688038          DOI: 10.1007/s13205-017-1019-8

Source DB:  PubMed          Journal:  3 Biotech        ISSN: 2190-5738            Impact factor:   2.406


  41 in total

1.  gyrA and parC mutations in quinolone-resistant clinical isolates of Pseudomonas aeruginosa from Nini Hospital in north Lebanon.

Authors:  Rayan Salma; Fouad Dabboussi; Imad Kassaa; Rami Khudary; Monzer Hamze
Journal:  J Infect Chemother       Date:  2012-07-21       Impact factor: 2.211

2.  International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004-2009.

Authors:  Victor D Rosenthal; Hu Bijie; Dennis G Maki; Yatin Mehta; Anucha Apisarnthanarak; Eduardo A Medeiros; Hakan Leblebicioglu; Dale Fisher; Carlos Álvarez-Moreno; Ilham Abu Khader; Marisela Del Rocío González Martínez; Luis E Cuellar; Josephine Anne Navoa-Ng; Rédouane Abouqal; Humberto Guanche Garcell; Zan Mitrev; María Catalina Pirez García; Asma Hamdi; Lourdes Dueñas; Elsie Cancel; Vaidotas Gurskis; Ossama Rasslan; Altaf Ahmed; Souha S Kanj; Olber Chavarría Ugalde; Trudell Mapp; Lul Raka; Cheong Yuet Meng; Le Thi Anh Thu; Sameeh Ghazal; Achilleas Gikas; Leonardo Pazmiño Narváez; Nepomuceno Mejía; Nassya Hadjieva; May Osman Gamar Elanbya; María Eugenia Guzmán Siritt; Kushlani Jayatilleke
Journal:  Am J Infect Control       Date:  2011-09-10       Impact factor: 2.918

3.  Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use.

Authors:  Melinda M Neuhauser; Robert A Weinstein; Robert Rydman; Larry H Danziger; George Karam; John P Quinn
Journal:  JAMA       Date:  2003-02-19       Impact factor: 56.272

4.  MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. MYSTIC Study Group (Americas).

Authors:  M A Pfaller; R N Jones
Journal:  J Antimicrob Chemother       Date:  2000-09       Impact factor: 5.790

5.  Real-time identification of Pseudomonas aeruginosa direct from clinical samples using a rapid extraction method and polymerase chain reaction (PCR).

Authors:  R I Jaffe; J D Lane; C W Bates
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

6.  Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010.

Authors:  Dawn M Sievert; Philip Ricks; Jonathan R Edwards; Amy Schneider; Jean Patel; Arjun Srinivasan; Alex Kallen; Brandi Limbago; Scott Fridkin
Journal:  Infect Control Hosp Epidemiol       Date:  2012-11-27       Impact factor: 3.254

7.  Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients.

Authors:  Helle Krogh Johansen; Samuel M Moskowitz; Oana Ciofu; Tacjana Pressler; Niels Høiby
Journal:  J Cyst Fibros       Date:  2008-03-20       Impact factor: 5.482

Review 8.  The role of multidrug efflux pumps in the antibiotic resistance of Pseudomonas aeruginosa and other gram-negative bacteria. Insights from the Society of Infectious Diseases Pharmacists.

Authors:  Jeffrey R Aeschlimann
Journal:  Pharmacotherapy       Date:  2003-07       Impact factor: 4.705

9.  Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011).

Authors:  Helio S Sader; David J Farrell; Robert K Flamm; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2013-12-06       Impact factor: 2.803

10.  Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002.

Authors:  Robert K Flamm; Mellany K Weaver; Clyde Thornsberry; Mark E Jones; James A Karlowsky; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

View more
  3 in total

Review 1.  Epidemiology of Multidrug-Resistant Pseudomonas aeruginosa in the Middle East and North Africa Region.

Authors:  Mahmood Al-Orphaly; Hamad Abdel Hadi; Faiha Kamaleldin Eltayeb; Hissa Al-Hail; Bincy Gladson Samuel; Ali A Sultan; Sini Skariah
Journal:  mSphere       Date:  2021-05-19       Impact factor: 4.389

2.  The First Saudi Report of Novel and Common Mutations in the gyrA and parC Genes Among Pseudomonas Spp. Clinical Isolates Recovered from Taif Area.

Authors:  Mohamed F El-Badawy; Emad M Eed; Asmaa S Sleem; Azza A K El-Sheikh; Ibrahim A Maghrabi; Sayed F Abdelwahab
Journal:  Infect Drug Resist       Date:  2022-07-16       Impact factor: 4.177

3.  Mutations in gyrB play an important role in ciprofloxacin-resistant Pseudomonas aeruginosa.

Authors:  Xinyuan Feng; Zhiqi Zhang; Xiaoxia Li; Yan Song; Jianbang Kang; Donghong Yin; Yating Gao; Nan Shi; Jinju Duan
Journal:  Infect Drug Resist       Date:  2019-02-08       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.